Predicting ICU Delirium in Critically Ill COVID-19 Patients Using Demographic, Clinical, and Laboratory Admission Data: A Machine Learning Approach.

Publication date: Jun 30, 2025

Delirium is a common and underrecognized complication among critically ill patients, associated with prolonged ICU stays, cognitive dysfunction, and increased mortality. Its multifactorial causes and fluctuating course hinder early prediction, limiting timely management. Predictive models based on data available at ICU admission may help to identify high-risk patients and guide early interventions. This study evaluated machine learning models used to predict delirium in critically ill patients with SARS-CoV-2 infections using a prospective cohort of 426 patients. The dataset included demographic characteristics, clinical data (e. g., comorbidities, medication, reason for ICU admission, interventions), and routine lab test results. Five models-Logistic Regression, Support Vector Machine, Decision Tree, Random Forest, and NacEFve Bayes-were developed using 112 features. Feature selection relied on Information Gain, and model performance was assessed via 10-fold cross-validation. The NacEFve Bayes model showed moderate predictive performance and high interpretability, achieving an AUC of 0. 717, accuracy of 65. 3%, sensitivity of 62. 4%, specificity of 68. 1%, and precision of 66. 2%. Key predictors included invasive mechanical ventilation, deep sedation with benzodiazepines, SARS-CoV-2 as the reason for ICU admission, ECMO use, constipation, and male sex. These findings support the use of interpretable models for early delirium risk stratification using routinely available ICU data.

Open Access PDF

Concepts Keywords
Basel COVID-19
Benzodiazepines delirium
Delirium ICU
machine learning
predictive modeling
SARS-CoV-2 infection

Semantics

Type Source Name
disease MESH Delirium
disease MESH Critically Ill
disease MESH COVID-19
disease MESH cognitive dysfunction
disease MESH causes
drug DRUGBANK Fosfomycin
disease MESH infections
disease MESH morbidity
disease MESH syndrome
disease MESH dementia
disease MESH clinical significance
drug DRUGBANK Gold
drug DRUGBANK Coenzyme M
disease MESH Confusion
drug DRUGBANK Etoperidone
disease IDO process
disease IDO intervention
disease IDO history
drug DRUGBANK Piroxicam
disease IDO blood
drug DRUGBANK Oxygen
drug DRUGBANK Potassium
drug DRUGBANK Creatinine
drug DRUGBANK Urea
drug DRUGBANK Nitrogen
drug DRUGBANK Propofol
drug DRUGBANK Isoxaflutole
disease MESH psychiatric disorders
disease MESH hypertension
disease MESH diabetes mellitus
disease MESH chronic kidney disease
disease MESH obesity
disease MESH dyslipidemia
disease MESH ischemic heart disease
disease MESH congestive heart failure
disease MESH pulmonary hypertension
disease MESH stroke
disease MESH hematologic malignancies
disease MESH liver disease
disease MESH hyperuricemia
disease MESH insomnia
disease MESH epilepsy
disease MESH Parkinson’s disease
disease MESH multiple sclerosis
disease MESH amyloidosis
drug DRUGBANK Midazolam
drug DRUGBANK Oxazepam
disease IDO symptom
drug DRUGBANK Fibrinogen Human
drug DRUGBANK Alkaline Phosphatase
pathway REACTOME SARS-CoV-2 Infection

Original Article

(Visited 3 times, 1 visits today)